Showing results (11-20 of 22) with videos related to
Sort By:
Pageof 3
Arthritis Research & Therapy|June 9, 2023
Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world studyLaure Gossec, Elke Theander, Soumya D Chakravarty, et al.Autoimmunity Reviews|June 25, 2025
Impact and management of warm autoimmune haemolytic anaemia associated with systemic lupus erythematosusGuillermo J Pons-Estel, Marta Mosca, Daniel J Wallace, et al.Blood|March 25, 2006
Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo in different pathologic conditionsGholamreza Hassanzadeh Ghassabeh, Patrick De Baetselier, Lea Brys, et al.Annals of the Rheumatic Diseases|November 25, 2021
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)Laura C Coates, Laure Gossec, Elke Theander, et al.Annals of the Rheumatic Diseases|February 25, 2022
Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio StudyLaure Gossec, Stefan Siebert, Paul Bergmans, et al.Arthritis Research & Therapy|June 23, 2023
Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world studyLaure Gossec, Stefan Siebert, Paul Bergmans, et al.Annals of the Rheumatic Diseases|January 4, 2023
Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world studyLaure Gossec, Stefan Siebert, Paul Bergmans, et al.Annals of the Rheumatic Diseases|June 24, 2021
Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study resultsJosef S Smolen, Stefan Siebert, Tatiana V Korotaeva, et al.Journal of Leukocyte Biology|December 14, 2004
Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammationGeert Raes, Lea Brys, Bhola K Dahal, et al.Rheumatology (Oxford, England)|June 29, 2022
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritisLaura C Coates, Christopher T Ritchlin, Laure Gossec, et al.Pageof 3